Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...